Enlightenment of HTA-driven Drug Access to Medical Insurance in Canada
Author information+
Show less
History+
Received
Published
2022-05-19
2022-06-20
Issue Date
2026-01-23
Abstract
Canada has accumulated some experience in decision-making of medical insurance drug access based on the results of health technology assessment. This paper systematically sorts out its management mechanism and technical points to provide reference for improving China's medical insurance drug access.
Enlightenment of HTA-driven Drug Access to Medical Insurance in Canada[J]. China Health Insurance. 2022, 0(6): 125-127 https://doi.org/10.19546/j.issn.1674-3830.2022.6.026
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Nicola Allen,Stuart R,Lawrence Liberti,et al.Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study[J].CMAJ OPEN,2016,4(4):674-678. [2] CADTH.Procedures for CADTH Reimbursement Reviews[R].2022,3. [3] CADTH.Procedures for the CADTH pan-Canadian Oncology Drug Review[R].2020,6. [4] 周挺,李洪超,马爱霞,等.加拿大药品统一审评制度及价格管理体系简析[J].中国卫生经济,2018,(37)2:94-96. [5] 王梦骁,邵蓉.加拿大统一药品审评制度的效果评价及启示[J].卫生经济研究,2016,(4) :41-44 [6] 常峰,席悦,李世勇,等.加拿大品牌药价格联合谈判机制及其对我国的启示[J].价格管理与实践,2016,(3):83-86.
